Short Interest in Qualigen Therapeutics, Inc. (NASDAQ:AIXC) Expands By 104.6%

Qualigen Therapeutics, Inc. (NASDAQ:AIXC) was the target of a large increase in short interest in the month of June. As of June 30th, there was short interest totaling 162,797 shares, an increase of 104.6% from the June 15th total of 79,560 shares. Based on an average trading volume of 263,099 shares, the short-interest ratio is presently 0.6 days. Approximately 0.8% of the company’s shares are short sold.

Qualigen Therapeutics Stock Up 7.6%

Qualigen Therapeutics stock opened at $0.99 on Wednesday. The firm has a market cap of $20.04 million, a price-to-earnings ratio of -0.15 and a beta of 0.49. Qualigen Therapeutics has a one year low of $0.90 and a one year high of $8.81. The business’s 50 day moving average is $1.25.

Qualigen Therapeutics (NASDAQ:AIXC) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.79) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Qualigen Therapeutics in a report on Friday, April 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.